Hetrombopag Olamine Tablet ( DrugBank: Hetrombopag )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
60 | Aplastic anemia | 3 |
60. Aplastic anemia
Clinical trials : 235 / Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05088655 (ClinicalTrials.gov) | June 25, 2021 | 12/10/2021 | A Bioequivalence Study of Hetrombopag in Healthy Subjects | Bioequivalence Study of Different Formulations of Hetrombopag Olamine Tablets in Healthy Subjects | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | 45 Years | All | 57 | Phase 1 | China |
2 | NCT05088642 (ClinicalTrials.gov) | September 28, 2020 | 12/10/2021 | A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects | A Phase I Clinical Study Evaluating the Pharmacokinetics and Safety of Hetrombopag Olamine Tablets in Subjects With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet | Jiangsu HengRui Medicine Co., Ltd. | NULL | Completed | 18 Years | 65 Years | All | 24 | Phase 1 | China |
3 | NCT05088174 (ClinicalTrials.gov) | September 3, 2020 | 12/10/2021 | A Trial of Hetrombopag in Healthy Subjects | A Single-Center, Single-Arm, Open-Label, Self-Controlled, Drug-Drug Interaction Study of Hetrombopag Olamine and Ciclosporin in Healthy Subjects | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet;Ciclosporin Soft Capsule | Jiangsu HengRui Medicine Co., Ltd. | NULL | Completed | 18 Years | 65 Years | All | 26 | Phase 1 | China |